Trade Names:Cefadroxil- Capsules 500 mg (as monohydrate)- Tablets 1 g (as monohydrate)- Powder for Oral Suspension 250 mg/5 mL- Powder for Oral Suspension 500 mg/5 mLApo-Cefadroxil (Canada)
Inhibits mucopeptide synthesis in bacterial cell wall.
Rapidly absorbed. C max is about 16 mcg/mL (500 mg dose) and 28 mcg/mL (1,000 mg dose).
20% protein bound.
More than 90% is excreted in the urine as unchanged drug within 24 h; t ½ is 78 to 96 min.
The t ½ is increased. Adjust dose.
Treatment of infections of urinary tract, skin and skin structures; treatment of pharyngitis and tonsillitis caused by susceptible strains of specific microorganisms.
Hypersensitivity to cephalosporins.
PO 1 to 2 g/day in single dose or 2 divided doses.Children
PO 30 mg/kg/day in single dose or 2 divided doses.
Oral suspension must be refrigerated and will remain stable for up to 14 days. Do not freeze. Shake well before use.
Inhibition of renal excretion of cefadroxil.
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets but not with enzyme-based tests (eg, Clinistix , Tes-tape ); false-positive test results for proteinuria with acid and denaturization-precipitation tests; false-positive direct Coombs test results in certain patients (eg, those with azotemia); false elevations in urinary 17-ketosteroid values.
Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy.
Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage.
Hepatic dysfunction, abnormal LFT results.
Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme and toxic epidermal necrolysis; serum sickness–like reactions (eg, skin rash, polyarthritis, arthralgia, fever); candidal overgrowth.
MonitorResponse to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not improve or appears to worsen.Side effects
Monitor patient for GI, DERM, and general body side effects, and signs of superinfection. Inform health care provider if noted and significant. Immediately report severe diarrhea, diarrhea containing blood or pus, or severe abdominal cramping.
Category B .
Excreted in breast milk.
In infants, consider benefits relative to risks. Drug may accumulate in newborns.
Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients because of possible cross-reactivity.
Use drug with caution in patients with renal function impairment. Dosage adjustment based on renal function may be required.
May result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Consider in patients in whom diarrhea develops.
Copyright © 2009 Wolters Kluwer Health.